Health‐related quality of life of patients with advanced breast cancer treated with everolimus plus exemestane versus placebo plus exemestane in the phase 3, randomized, controlled, BOLERO‐2 trial - Concepedia

Concepedia

Publication | Open Access

Health‐related quality of life of patients with advanced breast cancer treated with everolimus plus exemestane versus placebo plus exemestane in the phase 3, randomized, controlled, BOLERO‐2 trial

DOI Full Paper Access

100

Citations

24

References

2013

Year

Howard A. Burris, Fabienne Lebrun, Hope S. Rugo, J. Thaddeus Beck, Martine Piccart, Patrick Neven, José Baselga, Katarína Petráková, Gabriel N. Hortobágyi, Anna W. Komorowski,

Abstract

In patients with advanced breast cancer who develop disease progression after treatment with nonsteroidal aromatase inhibitors, EVE + EXE was associated with a longer TDD in global HRQOL versus PBO + EXE.

References

	Year	Citations

Page 1